Milena Sant, MD, of Istituto Nazionale dei Tumori, discusses the question of whether Europe is doing better in cancer care since the 1990s (Abstract LBA1).
Lisa Carey, MD, of the University of North Carolina, discusses heterogeneity, treatment response, and outcome in HER2-positive breast cancer.
M. Catherine Pietanza, MD, of Memorial Sloan Kettering Cancer Center, discusses rovalpituzumab tesirine, a promising DLL3-targeted antibody drug conjugate, the first precision treatment for small cell lung cancer (Abstract 7LBA).
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses the results from a phase III study investigating a multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma (Abstract 17LBA).
Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, discusses the ESMO initiative to make cancer drugs affordable.
Cora N. Sternberg, MD, of San Camillo Forlanini Hospital, summarizes a teaching lecture on new targets in renal cell carcinoma, and discusses what to expect for the future of treating RCC.
